Indegene Limited has recently clarified an oversight in its regulatory disclosures regarding the acquisition of a Spanish subsidiary. The company, which specializes in healthcare technology solutions, has provided additional details about the transaction in response to inquiries from stock exchanges.

Acquisition Details

Indegene Ireland Limited, a wholly-owned subsidiary of Indegene Limited, acquired Climacreative Spain S.L.U on November 19, 2024. The acquisition was made to establish a presence in Spain through a ready-made entity, commonly known as a 'shelf company.' Indegene paid €5,500 (equivalent to ₹485,136.30) for 100% shareholding of the Spanish entity.

Key Points of the Disclosure

• Acquisition Purpose: The primary objective was to obtain a pre-registered company to facilitate Indegene's expansion into the Spanish market.
• Entity Status: At the time of acquisition, Climacreative Spain S.L.U had no turnover or business operations.
• Transaction Classification: The company emphasized that this acquisition does not qualify as a material transaction and was not a related party transaction.
• Regulatory Compliance: The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company's Statement

In its communication to the stock exchanges, Indegene acknowledged the inadvertent omission in disclosing the acquisition earlier. The company stated, "The omission was purely unintentional. The Company remains committed to maintaining the highest standards of corporate governance and strives to ensure full compliance with all regulatory requirements."

Additional Information

Following the acquisition, the Spanish entity's name was changed to Indegene Spain S.L.U. The company was incorporated in Spain on July 29, 2024, just a few months before Indegene's acquisition.

Indegene's proactive disclosure and clarification demonstrate its commitment to transparency and regulatory compliance. As the company continues its expansion in Europe, this strategic move to establish a presence in Spain could potentially open new opportunities in the region's healthcare technology market.

Investors and stakeholders will likely keep a close eye on how Indegene leverages this new Spanish entity to further its business objectives in the European market.

Indegene , a digital-first life sciences commercialization company, has announced the launch of NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI) technology. This innovative tool aims to streamline complex medical writing workflows across clinical development, regulatory submissions, and beyond.

Revolutionizing Medical Writing

NEXT Medical Writing Automation is designed to address the challenges faced by medical writing teams, who are often under pressure to deliver precise, regulatory-ready documents within tight deadlines. The platform operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows.

Key Features and Benefits

• Integration with Existing Systems: NEXT seamlessly integrates with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents.
• Efficiency Boost: The platform offers automated scheduling, intelligent task assignments, and robust data flow integration, helping life sciences organizations scale operations efficiently.
• Compliance Focus: While enhancing efficiency, NEXT maintains a strong compliance backbone, crucial in an environment of growing document requirements and increased scrutiny.

Leveraging Cortex AI Engine

At the heart of NEXT is Indegene's Cortex AI engine, a life sciences-specialist knowledge engineering and multi-agent orchestration platform. Cortex enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance.

Industry Impact

Sameer Lal, SVP, Enterprise Medical Solutions at Indegene, commented on the launch: "We see this platform as more than automation—it's about elevating the entire practice of medical writing. Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting."

About Indegene

Indegene Limited is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech, and medical device companies develop products, get them to market, and grow their impact through the life cycle in a more effective, efficient, and modern way.

The launch of NEXT Medical Writing Automation reinforces Indegene's commitment to building AI-driven, domain-first solutions that help life sciences organizations modernize critical processes and meet business objectives with confidence.

For more information about Indegene and its services, visit www.indegene.com .